Programme Thesis
The Merck Research Grants program funds collaborative, early-stage research projects in key scientific areas, including a specific 2026 call for predictive in-vitro models of human neuroinflammatory diseases (e.g., Parkinson's) to address the lack of translatable animal models and enable disease-modifying therapies. It exists to foster innovation by partnering with external researchers, providing funding and industry guidance to de-risk novel approaches.
Selection Criteria
- Scientific excellence and innovation of the proposed research
- Relevance to the specific call: development of predictive in-vitro models for human neuroinflammatory diseases (e.g., Parkinson's)
- Evidence that the model recapitulates human disease pathology, including heterogeneity and relevant cellular/physiological features
- Feasibility and robustness of the proposed model (e.g., host-agnostic, easy to parameterize for the bioprocessing call; for neuro call, likely human-relevant, translatable)
- Potential for collaboration with Merck scientists and alignment with Merck's strategic interests
- Applicant's qualifications and institutional affiliation (open to all career stages, research institutions, universities, companies)
- Non-confidential information in initial application; full proposal and deep-dive workshop for finalists
Past Winners / Cohort Profiles
The page does not list past winners. However, based on the program's history since 2018, winners are typically researchers from academic institutions or companies who propose innovative, collaborative projects aligned with Merck's focus areas. They often have strong publication records and demonstrate potential for translational impact. Named examples are not available on this page.
Ideal Candidate Fingerprint
The ideal applicant is a researcher (any career stage) affiliated with a research institution, university, or company, proposing a cutting-edge, human-relevant in-vitro model for neuroinflammatory diseases. They should have a strong track record in relevant fields (e.g., neuroscience, cell biology, pharmacology, or computational modeling), demonstrate feasibility and innovation, and be eager to collaborate with Merck scientists to refine and advance their project.
Recommended Framing
For Eniola, the strongest angle is to leverage his computational modeling expertise to propose a predictive in-vitro model for neuroinflammatory diseases, specifically by integrating his CCT model's dynamical-systems approach with human-relevant data. His CCT model, which simulates reward-memory encoding and has been validated with Bayesian MCMC, can be adapted to model neuroinflammatory processes, offering a mechanistic, quantitative framework that addresses the call's need for translatable models. This aligns with his multi-domain skills and the program's emphasis on innovation and collaboration, despite his lack of wet-lab experience.
Watch Out
The call specifically requests 'in-vitro models' which typically implies experimental, laboratory-based systems. Eniola is a computational researcher with no apparent wet-lab experience, which could be a significant disadvantage. Additionally, the program requires affiliation with a research-based institution, university, or company; as an independent researcher, he may need to secure a host institution. His enrollment in an M.Sc. program could help, but he must clarify his affiliation status.
Research History
2026-08-04 20:28 · medium confidence
2026-08-04 15:07 · medium confidence